Company intelligence / Profile preview

Alizyme

Cambridge, Cambridgeshire, United Kingdom

Ownership: Private
Employees: ~10-50
Development stage: Commercial

Overview

Alizyme was a drug development company that had several products in clinical trials, including Renzapride for IBS-C (failed Phase III), Cetilistat for obesity, COLAL-PRED for ulcerative colitis (failed to meet efficacy targets in Phase III), and ATL-104 for mucositis (Phase IIa). The company went into administration in 2009 after failing to raise sufficient funds.

Therapeutic areas: GastroenterologyEndocrinology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

2 assets

prednisolone sodium metasulfobenzoate

Approved

1 more asset in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company LtdNorgine BV

Beyond the preview

Go deeper on Alizyme.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alizyme.

Explore the full profile